SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

A sharp AVAX rebound and heavier trading activity have fueled renewed attention, with traders linking the move to institutional and real-world-asset adoption narratives, including reported NYSE tokenization testing and expanded brokerage access. Bulls view the rally as a breakout and altcoin rotation, while skeptics call it another pump-and-dump with weak follow-through and persistent selling pressure.

TRON is a decentralized blockchain-based operating system designed to accelerate the decentralization of the internet and its underlying infrastructure. It serves as a global settlement layer for stablecoins and everyday digital purchases, providing a high-throughput environment to support large-scale decentralized applications. The network is governed by a decentralized autonomous organization (DAO), which allows the community to manage the protocol without a central authority. Its primary value proposition includes a unique resource model that utilizes bandwidth and energy to allow for high transaction volumes without traditional fee spikes.  The platform functions as a smart contract platform that enables the creation of decentralized applications and is compatible with the Ethereum Virtual Machine, allowing developers to easily migrate applications. TRON operates using a Delegated Proof of Stake consensus mechanism where token holders vote for 27 Super Representatives to verify transactions and maintain the ledger. This structure is built for scalability and fast finality, aiming to handle more transactions per second than many established legacy blockchains. Users can interact with the ecosystem for various purposes, including decentralized finance (DeFi) through platforms like JustLend DAO and decentralized storage via the BitTorrent File System.  Value moves through the system via its native utility token, TRX, which facilitates transactions and grants users access to network resources. Holders can lock their TRX in a staking mechanism to gain TRON Power, which is used to vote on network rules and elect Super Representatives, earning rewards for securing the network. Established by the TRON Foundation and led by founder Justin Sun, the project has transitioned into a community-led DAO. The ecosystem is supported by strategic partnerships with major global entities, including Samsung, which integrated TRON into its blockchain keystore, as well as BitTorrent, Opera, and Swisscom Blockchain.

Tron

TRON is drawing attention for its relative resilience and technical breakout, with traders highlighting steady upward momentum and strength while other major altcoins weaken. The community is broadly bullish on continued gains, though some technical views still call for consolidation or a corrective pullback; stablecoin payment activity is cited as fundamental support.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

A volatile rebound in PEPE alongside broader crypto strength is driving attention, with traders attributing the move to short-covering, liquidations, and a possible technical breakout. Bullish participants are discussing accumulation and further upside, while others characterize the move as low-volume speculation or a pump-and-dump and warn of a pullback.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

A new multi-year DefenCath supply agreement with DaVita, completing contracts with the five largest U.S. dialysis providers, alongside a quarterly beat and higher adjusted EBITDA outlook, is driving attention. Traders remain divided over whether the contract can offset post-TDAPA reimbursement pressure, with limited 2027 guidance and the timing of the REZZAYO sNDA adding uncertainty.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinzs move from Nasdaq to the NYSE coincided with unusually heavy trading volume, prompting speculation about index-fund repositioning, short selling, and possible market manipulation. Traders are divided between viewing the activity as a technical opportunity and focusing on the companys dividend and potential turnaround despite ongoing concerns about weak fundamentals.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Heightened attention centers on sharp, highly volatile rebounds and selloffs around Tezos depressed levels, with traders split between a potential bottom and accusations that the moves are coordinated or unsustainable pumps. Some bullish participants point to staking rewards, possible Tezos upgrades, and broader crypto catalysts, but no single confirmed development dominates the discussion.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Weak comparable-store sales and broader concerns about consumer spending, inflation, and fuel costs are driving Wingstops sharp selloff alongside other restaurant stocks. Traders remain divided, with bears warning of further downside while bulls view the decline as an oversold opportunity supported by franchise-led unit growth and long-term expansion.

PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of beverages, food, and snacks. It operates through the following business segments: PepsiCo Foods North America (PFNA), PepsiCo Beverages North America (PBNA), International Beverages Franchise (IB Franchise), Europe, Middle East and Africa (EMEA), Latin America Foods (LatAm Foods), and Asia Pacific Foods. The PFNA segment refers to the food businesses in the United States and Canada. The PBNA segment includes beverage businesses in the United States and Canada. The IB Franchise segment involves the international franchise beverage businesses, as well as the SodaStream business. The EMEA segment pertains to food businesses and beverage businesses with company-owned bottlers in Europe, the Middle East, and Africa. The LatAm Foods segment consists of food businesses in Latin America. The Asia Pacific Foods segment is associated in food businesses in Asia Pacific, including China, Australia and New Zealand, as well as India. The company was founded by Donald M. Kendall, Sr. and Herman W. Lay in 1965 and is headquartered in Purchase, NY.

PepsiCo Inc

Mixed quarterly results and a cautious North American consumer outlook have pushed PepsiCo toward multi-year lows, with traders citing weaker snack demand, margin pressure, inflation and GLP-1 usage as ongoing concerns. Bulls view the selloff as an attractive dividend-led value opportunity, while bears argue the weakness reflects a deeper deterioration in growth and capital allocation.

Grayscale Investments LLC - Grayscale Zcash ETF

Grayscale Zcash Trust ZEC

Grayscales announced 3-for-1 share split is driving attention to ZCSH, with traders viewing the lower entry price and improved liquidity as supportive for access to Zcash exposure amid a strong ZEC rally. Sentiment is broadly bullish, though some debate whether the trust is lagging or trading at a premium/discount to its underlying holdings has prompted profit-taking and caution.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

Bitcoins rally, supported by strong spot ETF inflows and forced short covering, has pushed IBIT into focus. Traders are divided between bullish breakout and accumulation views and caution over technical resistance, hawkish rate risks, and uncertainty surrounding the Clarity Act.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union

NVO's denecimig wins a positive European opinion for hemophilia A, with flexible dosing and a potential 2026 launch.

XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback

Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.

RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.

Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery

NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.

Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America

GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.

GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy

GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.

Definium Reports Second Phase III Success in Anxiety Disorder Program

DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.

GSK Presents Jideytro Data for Potential Use in First-Line NSCLC

GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.

AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study

ABBV's atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. It focuses on the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Why Did ALDX Stock Tank 70% Today?

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Microsoft Corp

Meta Platforms Inc

SELLAS Life Sciences Group Inc

Alphabet Inc Class A

CoreWeave Inc

SpaceX

Stocktwits Polls

$ALDX when’s the merger ….lol 

Ms. Deptula-Hicks is a senior biotechnology executive with over 30 years of experience across public and private life science companies, spanning therapeutics, diagnostics, medical devices, and emerging healthcare technologies. She has held senior executive, chief financial officer, board roles, and has extensive experience supporting companies through initial public offerings, major capital raises, strategic partnerships, and M&A transactions. Ms. Deptula-Hicks currently serves as the acting Chief Financial Officer of Normunity Inc., a clinical-stage biotech company focused on novel therapies to treat cancer. Previously, she served as Chief Financial Officer of F-star Therapeutics, Inc. Ms. Deptula-Hicks holds an M.B.A. from Rivier University and a B.S. in Accounting from Southern New Hampshire University.

$ALDX …quiet in here. At a LOSS…..for words?  Heavy bags here.  Sold only a little to buy other prospects. C’mon CEO, say something.  Or not. Lol. Lord, bring us back from the dead please.  GLTA.

S Shafer

$ALDX  
FYI - LEGAL UPDATE per ChatGPT-5: 
Judge Levenson issued a Memorandum & Order Aug 10, 2026 Massachusetts Federal District Court, docket # 1:26‑cv‑11510 
- S. Albonico appointed lead plaintiff, highest estimated loss >300K 
- Orrell and Bustamante motions are DENIED for lead plaintiff, lower losses 
- Rosen Law Firm approved as lead counsel per lead plaintiff request 
- ALDX has retained Goodwin Procter LLP for legal defense. Both Rosen &  GP are heavy hitters in securities fraud. 
- Scheduling Order (Aug 11–12, 2026) set the litigation calendar: 
TIMELINE: 
Amended/Expanded Complaint - Oct 9, 2026 - Access it through PACER 
Defendants’ Answer or Motion to Dismiss - Dec 8, 2026 
Plaintiff Opposition to Motion to Dismiss -  Jan 22, 2027 
Defendants' Reply - Feb 22, 2027 
 
Stay tuned - GLTA

Garth Griffiths

Wow, Big traders calling MLEC for a squeeze!    
   
Looks like he is right again, Loads of bulls shifting to MLEC now!  🚀    
   
The next parabolic low float runner?   
   
All eyes on are now on MLEC $ALDX

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALDX Aldeyra Therapeutics Inc

Fundamentals

Latest ALDX News